Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Page 1
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535.
N Engl J Med. 2022.
PMID: 35294813
Clinical Trial.
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH.
Lipsky PE, et al. Among authors: weiswasser m.
Ann Rheum Dis. 2022 Apr 27;81(8):1136-42. doi: 10.1136/annrheumdis-2022-222212. Online ahead of print.
Ann Rheum Dis. 2022.
PMID: 35477518
Free PMC article.
Item in Clipboard
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, Weiswasser M, Zhan X, Schafer PH, Werth VP.
Furie RA, et al. Among authors: weiswasser m.
Lupus Sci Med. 2022 Feb;9(1):e000581. doi: 10.1136/lupus-2021-000581.
Lupus Sci Med. 2022.
PMID: 35169036
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite